BORRBangladesh Open Research Repository
SearchSubmitAboutContact
BORRResearch for a Better Bangladesh.
AboutSubmit PaperContactTermsPolicyGitHub

© 2026 Bangladesh Open Research Repository.

Filters

Sort By

Sort by relevanceSort by dateSort by citations
Year Range
to

Results for “"Varsha Jain"”

9 results

Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children

Verified

Varsha Jain, Luis Rivera, Khalequ Zaman, Roberto A. Espos et al.

Journal: New England Journal of MedicineYear: 2013Citations: 141

BACKGROUND: Commonly used trivalent vaccines contain one influenza B virus lineage and may be ineffective against viruses of the other B lineage. We evaluated the efficacy of a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages. METHODS: In this multinational, phas...

Health SciencesMedicineEpidemiology
Read Source

Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons

Verified

Carine Claeys, Khalequ Zaman, Ghassan Dbaibo, Ping Li et al.

Journal: The Lancet Child & Adolescent HealthYear: 2018Citations: 79

Background Despite the importance of vaccinating children younger than 5 years, few studies evaluating vaccine prevention of influenza have been reported in this age group. We evaluated efficacy of an inactivated quadrivalent influenza vaccine (IIV4) in children aged 6-35 months. Methods In this pha...

Health SciencesMedicineEpidemiology
Read Source

Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons

Verified

Ghassan Dbaibo, Arshad Amanullah, Carine Claeys, Allen Izu et al.

Journal: The Pediatric Infectious Disease JournalYear: 2019Citations: 43

BACKGROUND: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6-35 months of age in a phase III, observer-blind trial. METHODS: The aim of this analysis was to estimate vaccine efficacy (VE) in preventing laboratory-confirmed influenza in each of 5 independent seasonal co...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

Clinical Presentation of Influenza in Children 6 to 35 Months of Age

Verified

Jasur Danier, Luis Rivera, Carine Claeys, Ghassan Dbaibo et al.

Journal: The Pediatric Infectious Disease JournalYear: 2019Citations: 19

BACKGROUND: In an exploratory analysis of an inactivated quadrivalent influenza vaccine (IIV4) trial in children 6-35 months without risk factors for influenza, we evaluated clinical presentation of influenza illness and vaccine impact on health outcomes. METHODS: This phase III trial was conducted ...

Health SciencesMedicineEpidemiology
Read Source

Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage

Verified

Thomas D. Stanton, Shaun P Keegan, Jabir A Abdulahi, Anne V Amulele et al.

Journal: medRxivYear: 2025Citations: 10

Background: Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against 70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations ...

Life SciencesBiochemistry, Genetics and Molecular BiologyMolecular MedicineOpen Access
Read Source

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Verified

Carine Claeys, Mamadou Dramé, José García-Sicilia, Khalequ Zaman et al.

Journal: BMC Infectious DiseasesYear: 2018Citations: 9

BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the change from ...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage

Verified

Thomas D. Stanton, Shaun P Keegan, Jabir A. Abdulahi, Anne V. Amulele et al.

Journal: PLoS MedicineYear: 2026Citations: 3

BACKGROUND: Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations...

Health SciencesMedicinePublic Health, Environmental and Occupational HealthOpen Access
Read Source

Assessment of Neutralizing Antibodies Against COVID-19: The Impact of Vaccination in Western Rajasthan

Verified

Varsha Choudhary, Prabhat Kiran Khatri, Palak Khinvasara, G.K. Aseri et al.

Journal: Indian Journal of Clinical BiochemistryYear: 2024Citations: 1
Health SciencesMedicineInfectious Diseases
Read Source

Machine Learning-Driven Detection of Malicious Websites for Consumer Protection

Verified

Arun Kumar Dubey, Achin Jain, Sarjana Singh, Sudhakar Kumar et al.

Year: 2025

The Internet has seen significant improvements in the number and type of web over the past few years. Resources such as online banking, gambling, and social networking sites have improved. As a result, large amounts of data are uploaded to the Internet daily. However, the Internet can be used as a t...

Physical SciencesComputer ScienceInformation Systems
Read Source
PreviousPage 1 of 1Next